The report discusses the epidemiological and social aspects of ageing, health and functional changes experienced with ageing, the impact of physical activity, assessment of the nutritional status of older persons, and nutritional guidelines for healthy ageing.
Procurement and supply management activities are fundamental to consistent and reliable access to essential medicines and health products. To reduce the impact of CVD, action needs to be taken to improve prevention, diagnosis, care and management of CVD diseases. Affordable essential medicines and t...echnologies to manage CVD disease must be available where and when they are required. Medicines and technologies need to be managed appropriately to ensure that the correct medicines are selected, procured in the right quantities, distributed to facilities in a timely manner, and handled and stored in a way that maintains their quality. This needs to be backed up by policies that enable sufficient quantities to be procured in order to reduce cost inefficiencies, ensure the reliability and security of the distribution system, and encourage the appropriate use of these health products. In order to avoid stock-outs and the disruption of treatment, all related activities need to be conducted in a timely manner, with performance continually monitored, and prompt action taken in response to problems that may arise. Additionally, medication must be dispensed correctly and used rationally by the healthcare provider and patient alike. The purpose of this guide is to explain the necessary steps.
more
March 2018, Vol. 108, (3 Suppl 1)
Guidance
Second Edition
Monitoring and Evaluation
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.11
HIV patient monitoring and case surveillance
PQDx 0179-012-00 WHO
PQDx Public Report
June/2017, version 4.0
PQDx 0144-043-00 WHO
PQDx Public Report
November/2016, version 4.0
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0
PQDx 0197-045-00 WHO
PQDx PR
March /2016, version 2.0
PQDx 0027-012-00 WHO
PQDx Public Report
May/2017, version 4.0
PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PQDx 0183‐060‐00 WHO
PQ Public Report
October/2016, version 5.0
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0
PQDx 0018-010-00 WHO
PQDx PR
July/2016, version 3.0
PQDx 0214-064-00
WHO PQDx PR
April/2016, version 3.0